Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12864431 | 1.00 | ALDH1A1 (0.52) | ALDH1A1GAASLC1A3SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL4249637 | 0.98 | ALDH1A1 (0.51) | ALDH1A1GAASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL6778635 | 0.86 | ALDH1A1 (0.49) | ALDH1A1GAASLC1A3SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL6777275 | 0.84 | ALDH1A1 (0.47) | ALDH1A1GAASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL24591314 | 0.83 | CTSS (0.49) | ALDH1A1GAASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL24591312 | 0.83 | CTSS (0.49) | ALDH1A1GAASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL10926891 | 0.81 | ALDH1A1 (0.50) | ALDH1A1SLC1A3SLC1A2SLC1A1ALOX5 | |
| SCHEMBL12240912 | 0.81 | ALDH1A1 (0.50) | ALDH1A1SLC1A3SLC1A2SLC1A1ALOX5 | |
| SCHEMBL180118 | 0.80 | SLC1A3 (0.54) | ALDH1A1SLC1A3SLC1A2SLC1A1ALOX5 | |
| SCHEMBL10305129 | 0.80 | ALOX5 (0.54) | ALDH1A1GAASLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220009946-A1 | FUSED HETEROCYCLIC BENZODIAZEPINE DERIVATIVES AND USES THEREOF | INTOCELL, INC. (KR) | 2022-01-13 | — | — | US | disclosed |
| US-7253198-B2 | Hydroxyethylamine derivatives for the treatment of Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-08-07 | — | — | US | disclosed |
| EP-1567488-B1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LTD (GB) | 2007-02-21 | — | — | EP | disclosed |
| CN-1735592-A | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LTD (GB) | 2006-02-15 | — | — | CN | disclosed |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
| EP-1567488-A1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2004050619-A1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2004-06-17 | — | — | WO | disclosed |
| EP-0427463-B1 | Substituted N-(imidazolyl)alkyl alanine derivatives | SMITHKLINE BEECHAM CORP (US) | 1995-03-08 | — | — | EP | disclosed |
| US-5248689-A | Hypotensive agents, congestive heart failure, renal failure or glaucoma | SMITHKLINE BEECHAM CORPORATION (US) | 1993-09-28 | — | — | US | disclosed |
| CN-1051555-A | N-(imidazolyl) the alkyl alanine derivatives that replaces | SMITHKLINE BEECHAM CORP (US) | 1991-05-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220009946-A1 | FUSED HETEROCYCLIC BENZODIAZEPINE DERIVATIVES AND USES THEREOF | GABRB2, GABRB3, GABRB1 | ALDH1A1 1347/4885GAA 1409/4885SLC1A3 882/4885 |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | BACE2, PSEN2, BACE1 | ALDH1A1 3102/4885GAA 80/4885SLC1A3 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.